Skip to main content

No PTC label warnings for Mirena Yet by Bayer

No PTC label warnings for Mirena Yet by Bayer

No PTC label warnings for Mirena Yet by Bayer

Introduction

Despite numerous studies suggesting links between Mirena (and other similar intrauterine birth control devices that use hormone levonorgestrel release) and pseudotumor cerebri (intracranial hypertension-IIH) and being the subject of several Pseudotumor cerebri (PTC) product liability lawsuits, Bayer Healthcare has shown no indications of updating the labels of Mirena IUD to adequately warn about a possible PTC link which includes symptoms like headaches, vision loss, and ringing of the ears.

No formal warning has yet been issued by the FDA to warn about the risk of PTC posed by the Mirena IUD, in spite of receiving hundreds of adverse event reports regarding complications from Mirena commonly involving side effects associated with PTC or IIH.

In April 2017, MDL No. 2767, (In Re:  Mirena IUS Levonorgestrel-Related Products Liability Litigation [No. II], was established under Judge Paul A. Engelmayer in the U.S. District Court for the Southern District of New York. Currently, more than 200 complaints are a part of this MDL and allege that the pharmaceutical manufacturer minimized the link between the Mirena IUD and the risk of serious brain injuries, including pseudotumor cerebri, benign intracranial hypertension, and idiopathic intracranial hypertension.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

NC to Get $150M to Boost Opioid Treatment, Recovery

Categories: Opioids

North Carolina will receive an additional $150 million from Purdue Pharma and the Sackler family as part of a national $7.4 billion settlement related to the opioid

SRI Gets FDA OK for High-Dose Naloxone Trial

Categories: Opioids

SRI has received authorization from the U.S. Food and Drug Administration (FDA) to begin Phase 1 clinical trials of a new, high-dose injectable naloxone formulation.

The approval was granted under an Investigational New Drug (IND)…

Spokane County to Get $5M in New Opioid Settlement

Categories: Opioids

Jurisdictions within Spokane County are set to receive nearly $4.7 million as part of a sweeping $7.4 billion nationwide settlement with Purdue Pharma and its owners, the Sackler family.

The agreement addresses the company’s role in fueling…

✍️ FREE—3000 Pages Medical Record Review Trial!                
No Contract. No Risk—Fully Customized, Free!

Only 10 Firms Accepted—Offer Ends June 30!